Only records released through the current editorial workflow appear here. Dates describe the underlying event and source, not the date CFCM discovered it. Independent scientific review is not implied unless explicitly stated.
No market records have completed editorial review yet.
No published signals match these filters.
Technology
Velociraptor compares cell populations across cytometry platforms
Velociraptor compares cell populations across cytometry platforms. Research comparisons do not establish prospective clinical diagnostic validation.
Event date
September 10, 2026
Source publication date
September 10, 2026
Research method. This summary establishes neither clinical device authorisation nor commercial availability.
Sysmex Europe and Cytek build a tiered clinical-flow workflow across more than a dozen European countries
Sysmex Europe and Cytek Biosciences announced a strategic collaboration across more than a dozen European countries, pairing Sysmex PS-10 automated sample preparation and XF-1600 routine clinical flow cytometry with Cytek Northern Lights-CLC spectral flow cytometry. The public announcement does not identify the participating countries, so Spain-specific inclusion remains unverified.
Event date
September 9, 2026
Source publication date
September 9, 2026
More than a dozen European countries; Spain specifically not verified in the public announcement
Strategic collaboration announced. Sysmex XF-1600 and PS-10 are positioned within Sysmex's clinical flow portfolio. Cytek states that Northern Lights-CLC and certain reagents are available for clinical use in the European Union and China; other Cytek products are RUO unless otherwise specified.
300K-funded Salamanca project evaluates freeze-dried blood for CLL
The University of Salamanca lists a CLL blood preservation validation project running from 1 December 2025 to 30 November 2026, led by Alberto Orfao and funded by 300K Solutions.
Event date
December 1, 2025
Source publication date
Spain
Project scheduled through 30 November 2026; results and indication-specific regulatory status not established here
ICCS 2026 adds an analytical-performance poster to CellMek SPS dry-tube automation
Beckman Coulter lists an ICCS 2026 poster on analytical performance of an automated dry-tube workflow using CellMek SPS, adding conference evidence to its existing dry-reagent automation platform.
Event date
Source publication date
ICCS 2026, Miami, USA / product availability jurisdiction-specific
Existing CellMek SPS platform with dry-reagent module; the poster is included in the ICCS 2026 program. The listing does not verify a completed presentation day or analytical results. LUCID custom panels are RUO; product/use status is jurisdiction-specific.
ICCS 2026 lists a label-free foundation model for automated viability in imaging flow cytometry
Waters Biosciences lists an ICCS 2026 poster on a label-free foundation model for automated viability assessment and functional assays in imaging flow cytometry. CFCM publishes the signal as WATCH because the public conference page does not disclose model-development or external-validation details.
Event date
Source publication date
ICCS 2026, Miami, USA / global research market
Included in the ICCS 2026 program in an RUO imaging-flow ecosystem. The listing does not verify an exact completed presentation day, diagnostic AI authorization or clinical performance.
ICCS 2026 tests CellView imaging as a single-cell check for rare plasma-cell MRD events
Waters Biosciences lists an ICCS 2026 poster using CellView imaging to verify the single-cell origin of rare abnormal plasma-cell events in measurable residual disease research. CFCM publishes the signal as WATCH because public conference material does not yet provide diagnostic-performance data.
Event date
Source publication date
ICCS 2026, Miami, USA / global RUO research market
Included in the ICCS 2026 program on the FACSDiscover A8/CellView research platform. The listing does not verify a completed presentation day. The A8/CellView platform is Research Use Only; the poster does not establish diagnostic authorization.
The Beckman Coulter ICCS 2026 program includes phenotypic flow cytometry and superRCA flow-cytometer-based genotyping as parallel MRD research workflows.
Event date
Source publication date
ICCS 2026, Miami, USA / global research market
Included in the ICCS 2026 program; relevant research workflow components are labelled Research Use Only. An exact completed presentation date is not established by the program.
ICCS 2026 puts therapy-aware flow reagents in focus: CD38(VHH) JK36 and TRBC2
Beckman Coulter's ICCS 2026 poster programme highlights RUO reagent strategies for difficult interpretation contexts: CD38(VHH) clone JK36 for CD38 detection in the presence of anti-CD38 therapy and TRBC1/TRBC2 conjugates for T-cell clonality research. These are not new product launches.
Event date
Source publication date
Global RUO catalogue; ICCS presentation in Miami, USA
CD38(VHH)-Alexa Fluor 488 clone JK36 and TCR Cβ2 (TRBC2)-APC clone SAM.2 are catalogued as Research Use Only. ICCS poster presence does not change regulatory status.
Curiox reports lower operator- and site-dependent variability with automated antibody cocktailing at ICCS 2026
Curiox reports ICCS 2026 poster data on the Pluto Antibody Cocktailing Wizard across 9-, 10- and 24-colour panels. The company reports lower operator/site variability and reduced hands-on time. CFCM publishes the signal as WATCH because the evidence is manufacturer-generated poster data rather than independent clinical validation.
Event date
Source publication date
ICCS 2026, Miami / online; product market status not reclassified from this poster
Existing Curiox Pluto automation platform. This record concerns new manufacturer-generated performance data, not a new regulatory authorization or product launch.
Primary evidence → What it demonstrates → Evidence boundary → Practical implications → CFCM view.
Manufacturer statements are identified as such. Unknown dates and unconfirmed availability remain unknown. Editorial priority is separate from publication approval.
Use the clinical resources to test the interpretation behind a technology or reagent claim. Discuss defined technical content or a disclosed sponsorship brief when appropriate.